ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

RGT Argent Biopharma Limited

6.50
0.00 (0.00%)
24 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Argent Biopharma Limited LSE:RGT London Ordinary Share AU0000326647 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.50 5.00 8.00 6.50 6.50 6.50 955 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Argent Biopharma Limited Director/PDMR Shareholding

12/09/2024 7:00am

RNS Regulatory News


RNS Number : 8288D
Argent Biopharma Limited
12 September 2024
 

 

12 September 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

PDMR Notification

 

Argent BioPharma Ltd (Argent BioPharma, RGT or the Company), has been notified of the following transaction which took place on 10 September 2024 whereby, Roby Zomer (Argent BioPharma's Managing Director & CEO) purchased 1,258,500 fully paid ordinary shares in Company at a price of A$0.40 each via an off-market purchase.

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

(a)

Name

Roby Zomer

2

Reason for the notification

 

(a)

Position

 

Managing Director and Chief Executive Officer

(b)

Initial notification/amendment

 

Initial

(c)

If amendment: reason

 

n/a

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor


Full name of entity

Argent BioPharma Ltd

 


Legal Entity Identifier Code

213800HRE3FQJ6RK4H10

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 

(a)

Description of the financial instrument, type of instrument

Fully Paid Ordinary Shares

(b)

Identification Code (ISIN)

 

AU0000326647

(c)

Nature of transaction

Off-market purchase.

(d)

Currency

Price

Volume

Total


AUD

0.40

1,258,500

$503,400


Aggregated information


AUD

0.40

1,258,500

$503,400

(e)

Date of transaction

 

10 September 2024

(f)

Place of transaction

 

Outside a trading venue

 

-Ends-

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma Limited               

Roby Zomer

CEO & Managing Director

+61 8 6555 2950

info@argentbiopharma.com

 

Argent BioPharma Limited

Rowan Harland

Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

 

About Argent BioPharma

Argent BioPharma Limited (the Company) (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the Central nervous system (CNS) and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBSGDCDDBDGSB

1 Year Argent Biopharma Chart

1 Year Argent Biopharma Chart

1 Month Argent Biopharma Chart

1 Month Argent Biopharma Chart

Your Recent History

Delayed Upgrade Clock